Wedbush Upgrades Abivax to Neutral, Lowers Price Target to $90

Benzinga Newsdesk www.benzinga.com Negative 57.6%

Neg 57.6% Neu 0% Pos 0%

Wedbush analyst David Nierengarten upgrades Abivax (NASDAQ:ABVX) from Underperform to Neutral and lowers the price target from $110 to $90.